Mouse models of experimental atherosclerosis.
暂无分享,去创建一个
P. Nastalek | R. Korbut | R Korbut | J Jawień | P Nastałek | J. Jawień
[1] Robert V Farese,et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. , 1995, The Journal of clinical investigation.
[2] R. Ross. Atherosclerosis is an inflammatory disease , 1999 .
[3] D. Steinberg,et al. Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[4] B. Paigen,et al. Variation in susceptibility to atherosclerosis among inbred strains of mice. , 1985, Atherosclerosis.
[5] R. Coleman,et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. , 1999, Cardiovascular research.
[6] R. Stocker,et al. Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] A. Gown,et al. Fatty streak expansion and maturation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. , 1987, Arteriosclerosis.
[8] K. Channon,et al. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[9] R. Coleman,et al. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. , 2000, Journal of cardiovascular pharmacology.
[10] L. Ignarro,et al. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[11] J. Breslow,et al. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. , 1998, Journal of cardiovascular pharmacology.
[12] R. Ross,et al. Studies of Hypercholesterolemia in the Nonhuman Primate: II. Fatty Streak Conversion to Fibrous Plaque , 1984, Arteriosclerosis.
[13] B. Malinowska,et al. Function of nociceptin and opioid OP4 receptors in the regulation of the cardiovascular system. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[14] D. Heistad,et al. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[15] S. Fazio,et al. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. , 1993, The Journal of clinical investigation.
[16] Colin N. Dewey,et al. Initial sequencing and comparative analysis of the mouse genome. , 2002 .
[17] S. Young,et al. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[18] B. Wieringa,et al. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. , 1994, Atherosclerosis.
[19] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[20] N. Maeda,et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.
[21] R. Williams,et al. Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.
[22] E. Rubin,et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.
[23] N. Maeda,et al. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[24] N. Maeda,et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[25] P. de Knijff,et al. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. , 1991, The Journal of clinical investigation.
[26] V. Ord,et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[27] J. Breslow. Lipoprotein metabolism and atherosclerosis susceptibility in transgenic mice. , 1994, Current opinion in lipidology.
[28] J. Breslow,et al. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Hammer,et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.
[30] H. Brewer,et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. , 1995, The Journal of clinical investigation.
[31] B. McManus,et al. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. , 1999, Circulation.
[32] Paul L Huang,et al. Accelerated Atherosclerosis, Aortic Aneurysm Formation, and Ischemic Heart Disease in Apolipoprotein E/Endothelial Nitric Oxide Synthase Double-Knockout Mice , 2001, Circulation.
[33] D. Rader,et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice , 1998, Nature Medicine.
[34] D. Steinberg,et al. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. , 1998, Journal of lipid research.
[35] A. Dembińska-kieć,et al. Correlation of the -3826A >G polymorphism in the promoter of the uncoupling protein 1 gene with obesity and metabolic disorders in obese families from southern Poland. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[36] M. Walski,et al. Ultrastructural alterations of endothelium covering advanced atherosclerotic plaque in human carotid artery visualised by scanning electron microscope. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[37] J. Drobnik,et al. Response of aorta connective tissue matrix to injury caused by vassopressin-induced hypertension or hypercholesterolemia. , 2000, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[38] N. Maeda,et al. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] Robert V Farese,et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). , 1993, The Journal of clinical investigation.
[40] A. Lusis,et al. Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. , 1993, The Journal of clinical investigation.
[41] R. Gerrity. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. , 1981, The American journal of pathology.
[42] J. Breslow,et al. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. , 1997, Biochemical and biophysical research communications.
[43] R. Ross,et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[44] E. Rubin,et al. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. , 1998, Journal of lipid research.
[45] Gerrity Rg. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. , 1981 .
[46] M. Callow,et al. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[47] E. Rubin,et al. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.
[48] R. Frants,et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.